91 Results for "

Lyn

" in MedChemExpress (MCE) Product Catalog:
Products (91)

91 Results for "Lyn" in MCE Product Catalog:

  • Isoforms Recommended:
  • Recombinant Proteins Recommended:
43
43 Publications Verification
Cat. No.: HY-10234
CAS No.: 379231-04-6
Purity:  99.92%
Synonyms: AZD0530
Target:  

Src Autophagy

Research Areas:  

Cancer

Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .
loading...
    loading...
43
43 Publications Verification
Cat. No.: HY-10234A
CAS No.: 893428-72-3
Purity:  99.24%
Synonyms: AZD0530 difumarate
Target:  

Src

Research Areas:  

Cancer

Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-12067
CAS No.: 841290-81-1
Purity:  96.70%
Target:  

Syk FLT3 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-11108
CAS No.: 841290-80-0
Purity:  99.80%
Target:  

Syk FLT3 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-B0789
CAS No.: 330161-87-0
Target:  

Src FAK Akt

Research Areas:  

Cancer

SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13038A
CAS No.: 901119-35-5
Purity:  99.70%
Synonyms: R788
Target:  

Syk FLT3

Research Areas:  

Inflammation/Immunology Cancer

Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13038
CAS No.: 1025687-58-4
Purity:  99.88%
Synonyms: R788Disodium
Target:  

Syk FLT3

Research Areas:  

Inflammation/Immunology Cancer

Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13038B
CAS No.: 914295-16-2
Purity:  99.51%
Synonyms: R788 disodium hexahydrate
Target:  

Syk FLT3

Research Areas:  

Inflammation/Immunology Cancer

Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-50868
CAS No.: 859212-16-1
Synonyms: INNO-406; NS-187
Target:  

Bcr-Abl Src Apoptosis

Research Areas:  

Cancer

Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15764
CAS No.: 364042-47-7
Purity:  99.75%
Synonyms: RK-20449
Target:  

Src Apoptosis

Research Areas:  

Cancer

A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, has high selectivity towards the Src family. A 419259 shows inhibitory effect for Src, Lck and Lyn with IC50 of 9 nM, <3 nM and <3 nM, respectively .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15764A
CAS No.: 1435934-25-0
Purity:  99.21%
Synonyms: RK 20449 trihydrochloride
Target:  

Src Apoptosis

Research Areas:  

Cancer

A 419259 trihydrochloride is a Src family kinases inhibitor with IC50s of 9 nM, 3 nM and 3 nM for Src, Lck and Lyn, respectively .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112852
CAS No.: 1315330-17-6
Purity:  98.47%
Target:  

Src Apoptosis

Research Areas:  

Cancer

TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101923
CAS No.: 2088939-99-3
Purity:  99.41%
Target:  

ULK Autophagy Apoptosis

Research Areas:  

Cancer

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101923B
CAS No.: 2310109-38-5
Purity:  99.55%
Target:  

ULK Autophagy Apoptosis

Research Areas:  

Cancer

LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10209
CAS No.: 790299-79-5
Purity:  99.95%
Synonyms: AB1010
Research Areas:  

Cancer

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10209A
CAS No.: 1048007-93-7
Purity:  99.51%
Synonyms: AB-1010 mesylate
Target:  

c-Kit PDGFR Src FGFR Apoptosis

Research Areas:  

Cancer

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-59047
CAS No.: 41964-07-2
Synonyms: MLR-1023
Target:  

Src

Research Areas:  

Metabolic Disease

Tolimidone is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-32736
CAS No.: 38647-11-9
Synonyms: NSC 165677; PG 492
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15749
CAS No.: 898280-07-4
Purity:  99.64%
Research Areas:  

Endocrinology Cancer

XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12072
CAS No.: 847950-09-8
Purity:  99.92%
Target:  

Src

Research Areas:  

Inflammation/Immunology

Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis .
loading...
    loading...